ProQR Therapeutics News

ProQR Therapeutics Announces Board Nomination and AGM

TipRanksApr 23 07:27 ET

Express News | ProQR Therapeutics NV: Intends to Change Board Structure From Two-Tier Structure to One-Tier Board

Moomoo 24/7Apr 23 07:15 ET

Express News | ProQR Nominates Martin Maier, Phd to Board and Announces Annual Meeting of Shareholders to Be Held May 22, 2024

Moomoo 24/7Apr 23 07:00 ET

ProQR Highlights Upcoming Presentations on Axiomer RNA Editing at ASGCT 27th Annual Meeting

ProQR Therapeutics NV (Nasdaq: PRQR) today announced it will present new preclinical data for its proprietary Axiomer RNA editing technology platform, including the first preclinical data for its AX-0810 pipeline program for cholestatic diseases targeting NTCP at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, May 7-11, 2024, in Baltimore, Maryland.

GlobeNewswireApr 22 16:31 ET

Leber Congenital Amaurosis Pipeline Insight 2024, Featuring Key Players ProQR Therapeutics, Editas Medicine, Atsena Therapeutics, Applied Genetic Technologies, IVERIC Bio and MeiraGTx

Yahoo FinanceApr 22 07:51 ET

Express News | ProQR Achieves Successful Defense of New Challenge to Its Axiomer™ Ip Portfolio

Moomoo 24/7Apr 19 07:00 ET

ProQR Therapeutics Is Maintained at Neutral by Citigroup

ProQR Therapeutics Is Maintained at Neutral by Citigroup

Dow JonesApr 18 12:16 ET

Express News | ProQR Therapeutics NV : Citigroup Raises Target Price to $2 From $1.8: Citigroup Raises Target Price to $2 From $1.8

Moomoo 24/7Apr 18 06:37 ET

ProQR Therapeutics Price Target Maintained With a $5.00/Share by HC Wainwright & Co.

ProQR Therapeutics Price Target Maintained With a $5.00/Share by HC Wainwright & Co.

Dow JonesMar 14 07:27 ET

ProQR Therapeutics Is Maintained at Buy by Chardan Capital

ProQR Therapeutics Is Maintained at Buy by Chardan Capital

Dow JonesMar 14 06:38 ET

Express News | Chardan Capital Maintains Buy on ProQR Therapeutics, Raises Price Target to $2.5

Moomoo 24/7Mar 14 06:27 ET

ProQR Therapeutics Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/14/2024 10.62% Chardan Capital $2 → $2.5 Maintains Buy 11/08/2023 76.99% Raymond James $5 → $4 Maintain

BenzingaMar 14 06:26 ET

Express News | ProQR Therapeutics Shares Are Trading Higher After the Company Reported a Year-over-year Increase in FY23 EPS Results

Moomoo 24/7Mar 13 15:16 ET

ProQR Reports FY Results

Seeking AlphaMar 13 07:10 ET

Express News | ProQR Therapeutics' 2023 Cash And Cash Equivalents Of €118.9M Is Expected To Provide Cash Runway Into Mid-2026

Moomoo 24/7Mar 13 07:10 ET

Express News | ProQR Therapeutics FY EPS $(0.38) Up From $(0.97) YoY

Moomoo 24/7Mar 13 07:09 ET

ProQR Therapeutics 2023 Loss EUR27.7M >PRQR

ProQR Therapeutics 2023 Loss EUR27.7M >PRQR

Dow JonesMar 13 07:01 ET

BMO Starts Korro at Outperform, Cites Upcoming Data for AATD Drug

Seeking AlphaFeb 27 16:06 ET

Express News | ProQR Says Japanese Axiomer Patent Upheld Following Opposition Against Its IP Estate For ADAR-Mediated RNA Editing

Moomoo 24/7Feb 15 07:20 ET

ProQR Announces Japanese Axiomer Patent Upheld Following Opposition Against Its Leading IP Estate for ADAR-mediated RNA Editing

LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (NASDAQ:PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced

GlobeNewswireFeb 15 07:00 ET